FLGT
Fulgent Genetics, Inc.Company Information
- Company Name
- Fulgent Genetics, Inc.
- CIK
- CIK0001674930
- Category
- Accelerated filer
- Ticker: Exchange
- FLGT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8071
- SIC Description
- Services-Medical Laboratories
- Ticker
- FLGT
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-03-05
- Last sale
- 2026-09-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 29,675
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,682,474
- Shares outstanding
- 28,005,000
- Ownership
- 52.43%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- -1.53%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 26 | 23 | 50 | 118 | 88 | 67 | 55 | 58 | 65 | 55 | 97 | 84 | ||||||
| Available For Sale Securities Debt Securities Current | 231 | 253 | 286 | - | - | - | 203 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 65 | 69 | 85 | 71 | 77 | 71 | 69 | 57 | 57 | 52 | 51 | 49 | ||||||
| Prepaid Taxes | 111 | 109 | 107 | - | - | - | 3 | - | - | - | - | - | ||||||
| Other Assets Current | 22 | 24 | 23 | 60 | 59 | 25 | 23 | 56 | 31 | 29 | 33 | 33 | ||||||
| Assets Current | 455 | 479 | 550 | 507 | 429 | 417 | 354 | 327 | 399 | 387 | 508 | 550 | ||||||
| Intangible Assets Net Excluding Goodwill | - | 154 | 133 | 135 | 131 | 133 | 135 | 137 | 139 | 141 | 143 | 144 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 294 | 328 | 369 | 412 | 484 | 494 | 570 | 602 | 526 | 540 | 424 | 384 | ||||||
| Property Plant And Equipment Net | 113 | 116 | 113 | 112 | 110 | 107 | 106 | 107 | 93 | 87 | 83 | 85 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | 68 | 68 | 68 | - | - | - | 65 | - | - | - | - | - | ||||||
| Other Intangible Assets Net | 81 | 85 | 65 | - | - | - | 70 | - | - | - | - | - | ||||||
| Goodwill | 54 | 54 | 25 | 25 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 142 | ||||||
| Other Assets Noncurrent | 24 | 25 | 23 | 23 | 23 | 33 | 33 | 39 | 32 | 33 | 35 | 38 | ||||||
| Assets | 1,089 | 1,156 | 1,214 | 1,215 | 1,200 | 1,206 | 1,220 | 1,234 | 1,232 | 1,230 | 1,235 | 1,358 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 16 | 21 | 19 | 18 | 19 | 18 | 18 | 20 | 20 | 20 | 15 | 16 | ||||||
| Accrued Liabilities Current | 24 | 35 | 34 | 23 | 22 | 17 | 24 | 24 | 26 | 26 | 31 | 21 | ||||||
| Contract With Customer Liability Current | 3 | 3 | 4 | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | ||||||
| Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities Current | 72 | 90 | 85 | 72 | 71 | 66 | 73 | 74 | 76 | 76 | 73 | 61 | ||||||
| Deferred Income Tax Liabilities Net | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 10 | ||||||
| Unrecognized Tax Benefits | 6 | 6 | 7 | 7 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 10 | ||||||
| Other Liabilities Noncurrent | 9 | 9 | 8 | 8 | 6 | 6 | 7 | 12 | 14 | 14 | 15 | 16 | ||||||
| Liabilities | 93 | 112 | 107 | 94 | 88 | 83 | 91 | 99 | 103 | 103 | 102 | 97 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 524 | 540 | 575 | 566 | 551 | 544 | 543 | 533 | 522 | 511 | 502 | 514 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 2 | 5 | 8 | 7 | 6 | 4 | -0 | 9 | -1 | -1 | 1 | -17 | ||||||
| Retained Earnings Accumulated Deficit | 476 | 505 | 530 | 553 | 560 | 579 | 590 | 596 | 611 | 620 | 633 | 761 | ||||||
| Stockholders Equity | 1,002 | 1,044 | 1,112 | 1,121 | 1,112 | 1,127 | 1,129 | 1,135 | 1,129 | 1,127 | 1,136 | 1,262 | ||||||
| Minority Interest | -6 | -6 | -5 | -5 | -5 | -4 | -4 | -4 | -4 | -3 | -3 | 3 | ||||||
| Liabilities And Stockholders Equity | 1,089 | 1,156 | 1,214 | 1,215 | 1,200 | 1,206 | 1,220 | 1,234 | 1,232 | 1,230 | 1,235 | 1,358 | ||||||
| Allowance For Doubtful Accounts Receivable | 26 | 21 | 21 | 22 | 21 | 21 | 20 | 25 | 25 | 26 | 25 | 29 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 35 | 35 | 35 | 34 | 34 | 34 | 34 | 33 | 33 | 33 | 32 | 32 | ||||||
| Shares Outstanding | 28 | 29 | 31 | 31 | 31 | 31 | 31 | 31 | 30 | 30 | 30 | 30 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFulgent Genetics, Inc. (FLGT) — SEC Financial Statements & Analysis
Fulgent Genetics, Inc. (FLGT) is a services-medical laboratories company, incorporated in DE. Fulgent Genetics, Inc. trades on Nasdaq as: FLGT. Fulgent Genetics, Inc. (FLGT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, Fulgent Genetics, Inc. carries a market cap of $574.66M, a P/E ratio of -6.67x, a P/B ratio of 0.57x, a P/S ratio of 1.77x, an enterprise value of $548.70M, and an EV/EBITDA multiple of -5.69x. On profitability, it posts a gross margin of 35.58%, an operating margin of -37.75%, a net margin of -26.59%, a Return on Equity (ROE) of -8.15%, a Return on Assets (ROA) of -7.53%, and a Return on Invested Capital (ROIC) of -11.24%. Per share, it reports EPS of $-3.08, diluted EPS of $-3.08, free cash flow per share of $-3.71, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 6.83% year-over-year, net income growth of 70.09% year-over-year, and EPS growth of 85.51% year-over-year. On the balance sheet, it maintains a current ratio of 6.34x, a quick ratio of 6.34x, working capital of $383.01M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.09, an interest coverage ratio of -1019.02x, free cash flow of $-103.79M (TTM), and net debt of $-25.96M. Figures sourced from SEC EDGAR.
- Market Cap
- $574.66M
- P/E TTM
- -6.67x
- EPS TTM
- $-3.08
- P/B TTM
- 0.57x
- ROE TTM
- -8.15%
- ROA TTM
- -7.53%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-103.79M
- Net Revenue TTM Growth 1Y
- 6.83%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Fulgent Genetics, Inc. in?
Fulgent Genetics, Inc. (FLGT) operates in the Services-Medical Laboratories industry.
What exchange does FLGT trade on?
Fulgent Genetics, Inc. (FLGT) trades on the Nasdaq.
Where is Fulgent Genetics, Inc. incorporated?
Fulgent Genetics, Inc. is incorporated in DE.
When was Fulgent Genetics, Inc. (FLGT)'s most recent SEC filing?
Fulgent Genetics, Inc. (FLGT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is FLGT's market cap?
Fulgent Genetics, Inc. (FLGT) has a market capitalization of $574.66M as of 2026-06-30.
What is FLGT's EPS (earnings per share)?
Fulgent Genetics, Inc. (FLGT)'s trailing twelve month EPS is $-3.08 as of 2026-06-30.
What is FLGT's ROE (return on equity)?
Fulgent Genetics, Inc. (FLGT)'s trailing twelve month Return on Equity (ROE) is -8.15% as of 2026-06-30.
What is FLGT's ROA (return on assets)?
Fulgent Genetics, Inc. (FLGT)'s trailing twelve month Return on Assets (ROA) is -7.53% as of 2026-06-30.
What is FLGT's ROIC (return on invested capital)?
Fulgent Genetics, Inc. (FLGT)'s trailing twelve month Return on Invested Capital (ROIC) is -11.24% as of 2026-06-30.
What is FLGT's EV/EBITDA?
Fulgent Genetics, Inc. (FLGT)'s trailing twelve month EV/EBITDA is -5.69x as of 2026-06-30.